Kimi Shah1, David Reyes-Gastelum2, Brittany L Gay2, Maria Papaleontiou3. 1. University of Michigan Medical School, Ann Arbor, Michigan. 2. Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, North Campus Research Complex, Ann Arbor, Michigan. 3. Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, North Campus Research Complex, Ann Arbor, Michigan. Electronic address: mpapaleo@med.umich.edu.
Abstract
OBJECTIVE: Thyroid hormone use is widespread, and prior studies have shown that over- and undertreatment with thyroid hormone are common. Our objective was to understand physician worry regarding risks associated with thyroid hormone therapy, specifically overtreatment or undertreatment. METHODS: A nationwide survey was administered to physician members of the Endocrine Society, the American Academy of Family Practice, and the American Geriatrics Society. Participants were asked how often they were worried about various risks that may be associated with thyroid hormone over- or undertreatment, that is, cardiovascular complications, bone complications, and poor quality of life due to overtreatment or undertreatment with thyroid hormone. Multivariable regression analyses were conducted to determine physician characteristics associated with each worry. RESULTS: The response rate was 63% (359 of 566); of those who responded, 128 (36%) were primary care physicians, 114 (32%) were endocrinologists, and 113 (32%) were geriatricians. Overall, 74 (21%) physicians reported that they frequently or always worried about cardiovascular complications, 74 (21%) about bone complications, 111 (31%) about the poor quality of life due to symptoms from undertreatment with thyroid hormone, and 87 (24%) about the poor quality of life due to symptoms from overtreatment with thyroid hormone. Endocrinologists were more likely to frequently or always worry about the patients' poor quality of life due to symptoms from overtreatment (odds ratio, 2.05; 95% confidence interval, 1.09-3.93) compared with primary care physicians. CONCLUSION: Up to one third of the physicians frequently or always worried about risks resulting from the thyroid hormone overtreatment or undertreatment. More research is needed across specialties to understand physician perceptions of how thyroid hormone therapy impacts the patients' quality of life.
OBJECTIVE: Thyroid hormone use is widespread, and prior studies have shown that over- and undertreatment with thyroid hormone are common. Our objective was to understand physician worry regarding risks associated with thyroid hormone therapy, specifically overtreatment or undertreatment. METHODS: A nationwide survey was administered to physician members of the Endocrine Society, the American Academy of Family Practice, and the American Geriatrics Society. Participants were asked how often they were worried about various risks that may be associated with thyroid hormone over- or undertreatment, that is, cardiovascular complications, bone complications, and poor quality of life due to overtreatment or undertreatment with thyroid hormone. Multivariable regression analyses were conducted to determine physician characteristics associated with each worry. RESULTS: The response rate was 63% (359 of 566); of those who responded, 128 (36%) were primary care physicians, 114 (32%) were endocrinologists, and 113 (32%) were geriatricians. Overall, 74 (21%) physicians reported that they frequently or always worried about cardiovascular complications, 74 (21%) about bone complications, 111 (31%) about the poor quality of life due to symptoms from undertreatment with thyroid hormone, and 87 (24%) about the poor quality of life due to symptoms from overtreatment with thyroid hormone. Endocrinologists were more likely to frequently or always worry about the patients' poor quality of life due to symptoms from overtreatment (odds ratio, 2.05; 95% confidence interval, 1.09-3.93) compared with primary care physicians. CONCLUSION: Up to one third of the physicians frequently or always worried about risks resulting from the thyroid hormone overtreatment or undertreatment. More research is needed across specialties to understand physician perceptions of how thyroid hormone therapy impacts the patients' quality of life.
Authors: Maria Papaleontiou; Brittany L Gay; Nazanene H Esfandiari; Sarah T Hawley; Megan R Haymart Journal: Endocr Pract Date: 2016-02-01 Impact factor: 3.443
Authors: Caroline K Kramer; Denise von Mühlen; Donna Kritz-Silverstein; Elizabeth Barrett-Connor Journal: Eur J Endocrinol Date: 2009-09-15 Impact factor: 6.664
Authors: Young-Jin Ko; Ji Young Kim; Joongyub Lee; Hong-Ji Song; Ju-Young Kim; Nam-Kyong Choi; Byung-Joo Park Journal: J Prev Med Public Health Date: 2014-01-29
Authors: Maria-Cristina Burlacu; Roberto Attanasio; Laszlo Hegedüs; Endre V Nagy; Enrico Papini; Petros Perros; Kiswendsida Sawadogo; Marie Bex; Bernard Corvilain; Chantal Daumerie; Brigitte Decallonne; Damien Gruson; Bruno Lapauw; Rodrigo Moreno Reyes; Patrick Petrossians; Kris Poppe; Annick Van den Bruel; David Unuane Journal: Thyroid Res Date: 2022-03-05